These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 26963842)

  • 21. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
    Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.
    Marder SR; Hakala MJ; Josiassen MK; Zhang P; Ouyang J; Weiller E; Weiss C; Hobart M
    Acta Neuropsychiatr; 2017 Oct; 29(5):278-290. PubMed ID: 27846922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brexpiprazole for the treatment of schizophrenia.
    Hsu WY; Lane HY; Lin CH
    Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
    Fleischhacker WW; Hobart M; Ouyang J; Forbes A; Pfister S; McQuade RD; Carson WH; Sanchez R; Nyilas M; Weiller E
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):11-21. PubMed ID: 27566723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Brexpiprazole for treatment of schizophrenia: a critical literature study].
    Spoelstra SK; Baas CAJ; Knegtering H
    Tijdschr Psychiatr; 2021; 63(1):48-55. PubMed ID: 33537974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
    Citrome L
    Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brexpiprazole.
    Markovic M; Gallipani A; Patel KH; Maroney M
    Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
    Forbes A; Hobart M; Ouyang J; Shi L; Pfister S; Hakala M
    Int J Neuropsychopharmacol; 2018 May; 21(5):433-441. PubMed ID: 29415258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study.
    Correll CU; Shi L; Weiss C; Hobart M; Eramo A; Duffy RA; Weiller E; Baker RA
    CNS Spectr; 2019 Oct; 24(5):507-517. PubMed ID: 30306884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
    Chrzanowski WK; Marcus RN; Torbeyns A; Nyilas M; McQuade RD
    Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies.
    Newcomer JW; Eriksson H; Zhang P; Weiller E; Weiss C
    Curr Med Res Opin; 2018 Dec; 34(12):2197-2205. PubMed ID: 29985680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
    Davis LL; Ota A; Perry P; Tsuneyoshi K; Weiller E; Baker RA
    Brain Behav; 2016 Oct; 6(10):e00520. PubMed ID: 27781135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
    Fava M; Ménard F; Davidsen CK; Baker RA
    J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of brexpiprazole - a new antipsychotic drug from the group of dopamine D2 receptor partial agonists.
    Bieńkowski P; Wichniak A
    Psychiatr Pol; 2024 Apr; 58(2):237-248. PubMed ID: 39003508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study.
    Krystal AD; Mittoux A; Meisels P; Baker RA
    Prim Care Companion CNS Disord; 2016 Sep; 18(5):. PubMed ID: 27835722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.